| Net income | 128.26M |
| Depreciation of property and equipment | 74.33M |
| Recognition of deferred revenue | |
| Amortization of definite-lived intangible and other assets | 137.2M |
| Amortization of program contract costs and net realizable value adjustments | |
| Original debt issuance discount paid | |
| Deferred tax provision | |
| Increase in accounts receivable, net | -77.12M |
| Decrease in income taxes receivable | |
| Increase in prepaid expenses and other current assets | -4.34M |
| Increase in other assets | |
| Increase in accounts payable and accrued liabilities | 36.29M |
| Increase in income taxes payable | -8.41M |
| Increase in other long-term liabilities | |
| Payments on program contracts payable | -84.63M |
| Other, net | 7.99M |
| Net cash flows from operating activities | 330.26M |
| Acquisition of property and equipment | -68.6M |
| Acquistion of intangibles | |
| Purchase of alarm monitoring contracts | -29.14M |
| Decrease in restricted cash | |
| Dividends and distributions from equity and cost method investees | |
| Investments in equity and cost method investees | -34.22M |
| Proceeds from insurance settlement | |
| Proceeds from the sale of assets | |
| Loans to affiliates | |
| Proceeds from loans to affiliates | |
| Net cash flows (used in) from investing activities | -557.53M |
| Proceeds from notes payable, commercial bank financing and capital leases | 1.01B |
| Repayments of notes payable, commercial bank financing and capital leases | -653.99M |
| Proceeds from exercise of stock options, including excess tax benefits of share based payments of $0.7 million and $0 million, respectively | |
| Dividends paid on Class A and Class B Common Stock | -49.67M |
| Payments for deferred financing costs | -15.6M |
| Proceeds from Class A Common Stock sold by variable interest entity | |
| Noncontrolling interests distributions | |
| Repayments of notes and capital leases to affiliates | |
| Net cash flows used in financing activities | 181.84M |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | -45.43M |
| CASH AND CASH EQUIVALENTS, beginning of period | 149.97M |
| CASH AND CASH EQUIVALENTS, end of period | 104.55M |